Lucentis PFS (Ranibizumab)
Lucentis PFS (Ranibizumab Injection) is a treatment for a variety of vision-threatening eye conditions, including neovascular (wet) age-related macular degeneration (AMD), macular edema after retinal vein occlusion (RVO), myopic choroidal neovascularization (mCNV), and diabetic macular edema (DME). Lucentis PFS, designed with precision, provides hope and improved vision to those suffering from these severe eye disorders.
Why Choose Lucentis PFS (Ranibizumab)?
- Clinically Proven: Lucentis PFS has been tested in numerous clinical trials to demonstrate its efficacy in improving vision and delaying disease progression.
- Safety Profile: Lucentis PFS has a well-established safety profile, making it a reliable choice for healthcare providers.
- Convenience: The prefilled syringe type streamlines administration, allowing for faster and more efficient treatments.
- Treatment Flexibility: Provides dosage flexibility to address patients’ various demands and particular situations.
How to Use Lucentis PFS (Ranibizumab)?
- Confirm that Lucentis PFS (Ranibizumab) is appropriate for the patient’s eye condition (wet AMD, RVO, mCNV, and DME).
- Inspect the syringe: Make sure the fluid is clear to slightly opalescent, with no particle debris or discoloration.
- Prepare the Patient: Explain the operation, acquire consent, and emphasize aftercare and follow-ups.
- Aseptic Technique: Maintain sterile conditions during the injection procedure.
- Anesthesia and Disinfection: Administer anesthetic and carefully sanitize the eye region.
- Lucentis should be injected intravitreally as directed, usually at a dose of 0.5 mg each month.
- Post-Injection Care: Provide advice on care and urge patients to seek immediate medical attention if they experience any unpleasant symptoms.
- Follow-up: Schedule check-ups to evaluate and adjust treatment as necessary.
Important Safety Information about Lucentis PFS
- Endophthalmitis and Retinal Detachments: Intravitreal injections, such as those with Lucentis, can raise the risk of endophthalmitis and retinal detachment. Patients should be continuously monitored during their treatment.
- Intraocular Inflammation: Lucentis has been linked to cases of intraocular inflammation. Patients should report any symptoms indicating an inflammatory reaction.
- Thromboembolic Events: The intravitreal use of VEGF inhibitors, such as Lucentis, may increase the risk of arterial thromboembolic events.
- Inform your healthcare practitioner about all medications you’re taking to avoid potential drug interactions.
Fact Table for Lucentis PFS
Facts | Details |
Generic Name | Ranibizumab |
Brand Name | Lucentis |
Form | Prefilled Syringe (PFS) |
FDA Approval | Yes (Approval dates vary based on specific indications) |
Indications | – Neovascular (Wet) Age-Related Macular Degeneration (AMD) – Macular Edema following Retinal Vein Occlusion (RVO) – Diabetic Macular Edema (DME) – Diabetic Retinopathy (DR) – Myopic Choroidal Neovascularization (mCNV) |
Mechanism of Action | Ranibizumab is a monoclonal antibody fragment designed to inhibit vascular endothelial growth factor A (VEGF-A), a protein that plays a critical role in angiogenesis (formation of new blood vessels) and increased permeability of the vessels, both of which are involved in the pathophysiology of its indicated diseases. |
Dosage | Dosage varies by indication; commonly administered as an injection into the vitreous humor of the eye by a healthcare professional. |
Administration | Intravitreal injection |
Common Side Effects | – Eye pain – Increased intraocular pressure – Vitreous floaters – Conjunctival hemorrhage |
Contraindications | – Infection in or around the eye – Ocular or periocular infections |
Precautions | – Proper aseptic injection technique must be used to prevent infections.- Monitor patients for signs of endophthalmitis and intraocular inflammation. |
Interactions | There are no well-documented significant drug interactions with systemic medications, given their localized action. However, caution should be exercised when used concurrently with other ocular treatments. |
Storage | Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. |
Common Side Effects of Lucentis PFS
Like all medications, Lucentis PFS (Ranibizumab) can cause side effects, although not everybody gets them. Understanding these side effects can help you use this medication safely and effectively.
- Eye pain
- Increased intraocular pressure
- Vitreous floaters
- Conjunctival hemorrhage
If you experience any of these side effects or others, make sure to discuss them with your healthcare provider. They can offer advice and may adjust your treatment if necessary. Report any severe or unexpected side effects immediately.
How Can You Buy Lucentis PFS (Ranibizumab)?
You can order Lucentis PFS (Ranibizumab) using these methods on our website:
- Order Online
- Order by Phone
- Order by Fax
- Order your refills
Visit our How to order page.